AU2001284909A1 - Urea compounds and methods of uses - Google Patents

Urea compounds and methods of uses

Info

Publication number
AU2001284909A1
AU2001284909A1 AU2001284909A AU2001284909A AU2001284909A1 AU 2001284909 A1 AU2001284909 A1 AU 2001284909A1 AU 2001284909 A AU2001284909 A AU 2001284909A AU 2001284909 A AU2001284909 A AU 2001284909A AU 2001284909 A1 AU2001284909 A1 AU 2001284909A1
Authority
AU
Australia
Prior art keywords
uses
methods
urea compounds
urea
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001284909A
Other versions
AU2001284909B2 (en
Inventor
Benny Askew
Arup Ghose
Andrew Hague
Tae Seong Kim
Ellen Laber
Aiwen Li
Brian Lian
Gang Liu
Mark Henry Norman
Vincent Santora
Leon Smith
Andrew Tasker
Christopher Tegley
Kevin Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US22579300P priority Critical
Priority to US60/225,793 priority
Priority to US09/930,753 priority patent/US20020173507A1/en
Priority to US09/930,753 priority
Application filed by Amgen Inc. filed Critical Amgen Inc.
Priority to PCT/US2001/025472 priority patent/WO2002014311A2/en
Publication of AU2001284909A1 publication Critical patent/AU2001284909A1/en
Application granted granted Critical
Publication of AU2001284909B2 publication Critical patent/AU2001284909B2/en
Application status is Ceased legal-status Critical
Anticipated expiration legal-status Critical

Links

AU2001284909A 2000-08-15 2001-08-15 Urea compounds and methods of uses Ceased AU2001284909B2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US22579300P true 2000-08-15 2000-08-15
US60/225,793 2000-08-15
US09/930,753 US20020173507A1 (en) 2000-08-15 2001-08-14 Urea compounds and methods of uses
US09/930,753 2001-08-14
PCT/US2001/025472 WO2002014311A2 (en) 2000-08-15 2001-08-15 Urea compounds and methods of uses

Publications (2)

Publication Number Publication Date
AU2001284909A1 true AU2001284909A1 (en) 2002-05-23
AU2001284909B2 AU2001284909B2 (en) 2005-10-13

Family

ID=22846259

Family Applications (2)

Application Number Title Priority Date Filing Date
AU8490901A Pending AU8490901A (en) 2000-08-15 2001-08-15 Urea compounds and methods of uses
AU2001284909A Ceased AU2001284909B2 (en) 2000-08-15 2001-08-15 Urea compounds and methods of uses

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU8490901A Pending AU8490901A (en) 2000-08-15 2001-08-15 Urea compounds and methods of uses

Country Status (12)

Country Link
US (1) US20020173507A1 (en)
EP (1) EP1309589B1 (en)
JP (1) JP2004521072A (en)
AT (1) AT320426T (en)
AU (2) AU8490901A (en)
CA (1) CA2418273A1 (en)
DE (1) DE60118003T2 (en)
DK (1) DK1309589T3 (en)
ES (1) ES2260277T3 (en)
MX (1) MXPA03001357A (en)
PT (1) PT1309589E (en)
WO (1) WO2002014311A2 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1305470A (en) 1998-04-10 2001-07-25 日本烟草产业株式会社 Amidine compounds
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (en) 1999-01-13 2002-10-15 バイエル コーポレイション As p38 kinase inhibitors ω- carboxyaryl substituted diphenyl ureas
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
ES2275931T5 (en) 2001-12-03 2018-10-23 Bayer Healthcare Llc Aryl urea compounds in combination with other cytostatic or cytotoxic agents for the treatment of human cancers
JP2005516005A (en) * 2001-12-07 2005-06-02 バーテクス ファーマスーティカルズ インコーポレイテッド Gsk-3 inhibitors useful pyrimidine based compounds
JP2005514383A (en) * 2001-12-13 2005-05-19 ファーマサイクリクス,インコーポレイテッド Cancer combination therapy
DK1478358T3 (en) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylate for the treatment of diseases characterized by abnormal angiogenesis
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
ITMI20021419A1 (en) * 2002-06-27 2003-12-29 Univ Degli Studi Milano New derivatives of 2-pyridine acetic acid as compounds with activity 'antiproliferative
KR101124245B1 (en) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 Aryl carbonyl derivatives as therapeutic agents
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
WO2004041813A1 (en) * 2002-10-30 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2004055154A2 (en) * 2002-12-17 2004-07-01 Centre National De La Recherche Scientifique (Cnrs) Use of purine derivatives for inducing differentiation of supernumerary hair cells and deiters' cells in the developing organ of corti for treating deafness
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
AU2003300099A1 (en) * 2003-01-02 2004-07-29 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta
ES2387909T3 (en) 2003-01-14 2012-10-03 Cytokinetics, Inc. Compounds, compositions and procedures for treating heart failure
EP1587800A1 (en) * 2003-01-27 2005-10-26 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
CA2519265A1 (en) * 2003-03-28 2004-10-07 Pharmacia & Upjohn Company Llc Positive allosteric modulators of the nicotinic acetylcholine receptor
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
ES2288694T3 (en) 2003-05-20 2008-01-16 Bayer Pharmaceuticals Corporation Diaril ureas for diseases mediated by the receiver of the growth factor derived from plates.
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
EA010485B1 (en) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Derivative n, n'-diphenylurea, the pharmaceutical composition (variants) and a method of treating and preventing diseases and conditions of its use (variants)
MXPA06007667A (en) 2004-01-06 2006-09-01 Novo Nordisk As Heteroaryl-ureas and their use as glucokinase activators.
CA2559665A1 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
JP4602686B2 (en) * 2004-04-15 2010-12-22 広栄化学工業株式会社 Process for producing 2,6-dihalogeno-4-arylpyridines
DE602005020611D1 (en) 2004-04-28 2010-05-27 Vertex Pharma Compositions suited as inhibitors of rock and other protein kinases
EP2295426A1 (en) * 2004-04-30 2011-03-16 Bayer HealthCare, LLC Substituted pyrazolyl urea derivatives useful in the treatment of cancer
AU2005264988B2 (en) 2004-06-17 2011-09-22 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
NZ554555A (en) 2004-10-20 2011-09-30 Univ California Cyclohexyl-urea derivatives as improved inhibitors for the soluble epoxide hydrolase
WO2006053109A1 (en) * 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
CA2586870A1 (en) * 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
JP2008523071A (en) 2004-12-07 2008-07-03 ルーカス ファーマシューティカルズ, インコーポレイテッド Urea inhibitor of MAP kinase
FR2881426B1 (en) * 2005-02-03 2007-03-30 Aventis Pharma Sa Substituted pyrolles and imidazoles, compositions containing the same, process for frabrication and use
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
EP1959960B1 (en) 2005-12-15 2013-04-10 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
EP1962852B1 (en) 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
AR059826A1 (en) 2006-03-13 2008-04-30 Univ California Urea inhibitors conformationally constrained soluble epoxide hydrolase
JP2010504362A (en) * 2006-09-25 2010-02-12 アレテ セラピューティクス, インコーポレイテッド Soluble epoxide hydrolase inhibitor
US7790756B2 (en) * 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
JP2010527367A (en) * 2007-05-15 2010-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Urotensin II receptor antagonist
JPWO2009096198A1 (en) * 2008-02-01 2011-05-26 一般社団法人ファルマIp New biaryl derivatives
US20100041642A1 (en) * 2008-08-15 2010-02-18 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
UY33200A (en) 2010-01-26 2011-08-31 Sanofi Aventis Derivatives 3-heteroaroylamino-oxygen substituted propionic acid and their use as pharmaceuticals
US9296693B2 (en) 2010-01-29 2016-03-29 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
WO2011130740A2 (en) * 2010-04-16 2011-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of rho associated protein kinase (rock) and methods of use
EP2701699B1 (en) 2011-04-28 2019-10-16 The Broad Institute, Inc. Inhibitors of histone deacetylase
CA2841911A1 (en) 2011-07-26 2013-01-31 Sanofi Substituted 3 - (thiazole - 4 - carbonyl) - or 3 - (thiazole - 2 - carbonyl) - aminopropionic acid derivatives and their use as pharmaceuticals
US9409868B2 (en) 2012-01-24 2016-08-09 H. Lee Moffin Cancer Center and Research Institute, Inc. Inhibitors of rho associated protein kinases (ROCK) and methods of use
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP2877444A1 (en) 2012-07-27 2015-06-03 The Broad Institute, Inc. Inhibitors of histone deacetylase
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
TW201506024A (en) 2013-07-02 2015-02-16 Squibb Bristol Myers Co Tricyclic carboxamide derivatives as potent ROCK inhibitors
US9663529B2 (en) 2013-07-02 2017-05-30 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
EA029981B1 (en) * 2013-08-27 2018-06-29 Бристол-Майерс Сквибб Компани Ido inhibitors
WO2018184019A1 (en) * 2017-03-31 2018-10-04 Curza Global, Llc Compositions and methods comprising substituted 2-aminoimidazoles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
UA71904C2 (en) * 1997-12-22 2000-12-15 Compounds and methods of treating by inhibiting raf kinase using heterocyclic substituted urea derivatives
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents

Similar Documents

Publication Publication Date Title
AU2002324775A8 (en) Architecture tool and methods of use
PT1309589E (en) Compounds of urea and methods of utilization
SI1448523T1 (en) Heterocyclic compounds and methods of use
EP1408986A4 (en) Proteomimetic compounds and methods
AU2001253914A1 (en) Targeted modification of chromatin structure
PL218883B1 (en) Application of antibody
AUPP913999A0 (en) Novel chemical compounds and their use
AU2002245142A1 (en) Prokaryotically produced antibodies and uses thereof
AU4145200A (en) Cyclic compounds and uses thereof
AU2002306768A1 (en) Expression profiles and methods of use
AU2001249072A1 (en) Lipase-containing composition and methods of use thereof
AU2002226486A1 (en) Novel c-glycoside derivatives and use thereof
AU2002330943A1 (en) Immunomodulatory compounds and methods of use thereof
AU2001259270A1 (en) Methods and compositions utilizing quinazolinones
AU3149300A (en) Fasteners and methods of making fasteners
AU2003275311A1 (en) Solid micro-perforators and methods of use
AU2002253890A1 (en) Substituted Amine Derivatives and Methods of Use
AU3652102A (en) Compounds and their uses
AU2001247905A1 (en) 2-alkylidene-19-nor-vitamin D compounds and their therapeutic uses
AU2002364528A1 (en) Bio-implant and method of making the same
AU2468401A (en) Underreamer and method of use
AU2002361563A1 (en) Anti-tombstoning structures and methods of manufacture
AU2001290784A1 (en) Antimicrobial peptides and methods of use
AU6117000A (en) Novel polynucleotides and method of use thereof
AU2001297790A1 (en) Piezoelectric micro-transducers, methods of use and manufacturing methods for same